Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study

被引:0
|
作者
Tini, Giacomo [1 ]
Musumeci, Beatrice [1 ]
Milani, Paolo [2 ,3 ]
Zampieri, Mattia [4 ]
Caponetti, Angelo Giuseppe [5 ,6 ]
Fabris, Francesca [2 ,3 ]
Foli, Andrea [2 ,3 ]
Argiro, Alessia [4 ]
Mazzoni, Carlotta [4 ]
Gagliardi, Christian [5 ,7 ]
Longhi, Simone [5 ,7 ]
Saturi, Giulia [6 ,7 ]
Vergaro, Giuseppe [8 ]
Aimo, Alberto [8 ]
De Fazio, Ludovica [1 ]
Varra, Guerino Giuseppe [9 ]
Serenelli, Matteo [10 ]
Fabbri, Gioele [10 ]
De Michieli, Laura [11 ,12 ]
Palmiero, Giuseppe [13 ]
Ciliberti, Giuseppe [14 ]
Carigi, Samuela [15 ]
Zanoletti, Margherita [16 ]
Mandoli, Giulia Elena [17 ]
Lucchi, Giulia Ricci [18 ]
Rella, Valeria [19 ]
Monti, Enrico [20 ]
Gardini, Elisa [20 ]
Bartolotti, Michela [21 ]
Crotti, Lia [20 ,22 ]
Merli, Elisa [23 ]
Mussinelli, Roberta [2 ,3 ]
Vianello, Pier Filippo [16 ]
Cameli, Matteo [17 ]
Marzo, Francesca [15 ]
Guerra, Federico [14 ]
Limongelli, Giuseppe [13 ]
Cipriani, Alberto [11 ,12 ]
Perlini, Stefano [2 ,3 ]
Obici, Laura [2 ,3 ]
Perfetto, Federico [4 ]
Barbato, Emanuele [1 ]
Porto, Italo [16 ,24 ]
Sinagra, Gianfranco [7 ,9 ]
Merlo, Marco [7 ,9 ]
Emdin, Michele [8 ]
Biagini, Elena [5 ,7 ]
Cappelli, Francesco [4 ]
Palladini, Giovanni [2 ,3 ]
Canepa, Marco [16 ,24 ]
机构
[1] Sapienza Univ Rome, Dept Cardiol, Dept Clin & Mol Med, Rome, Italy
[2] Univ Pavia, Dept Mol Med, Pavia, Italy
[3] Fdn Ist Ricovero & Cura Carattere Sci IRCCS Policl, Amyloidosis Res & Treatment Ctr, Pavia, Italy
[4] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Florence, Italy
[5] IRCCS Azienda Osped Univ Bologna, St Orsola Hosp, Cardiol Unit, Bologna, Italy
[6] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[7] European Reference Network Rare, Low Prevalence & Complex Dis, Heart ERN GUARD Heart, London, England
[8] Scuola Super Sant Anna, Fdn Toscana Gabriele Monasterio, Interdisciplinary Ctr Hlth Sci, Pisa, Italy
[9] Univ Trieste, Azienda Sanit Univ Giuliano Isontina ASUGI, Ctr Diag & Treatment Cardiomyopathies, Cardiovasc Dept, Trieste, Italy
[10] Univ Ferrara, Cardiol Ctr, Ferrara, Italy
[11] Univ Padua, Dept Cardiothoraco Vasc Sci & Publ Hlth, Padua, Italy
[12] Univ Hosp Padova, Cardiol Unit, Padua, Italy
[13] Univ Campania Luigi Vanvitelli, Monaldi Hosp, AORN Colli, Inherited & Rare Cardiovasc Dis Unit, Naples, Italy
[14] Marche Polytech Univ, Univ Hosp Lancisi Umberto I Salesi, Dept Biomed Sci & Publ Hlth, Cardiol & Arrhythmol Clin, Ancona, Italy
[15] Infermi Hosp, Cardiol Unit, Rimini, Italy
[16] Osped Policlin San Martino IRCCS, Cardiol Unit, Genoa, Italy
[17] Univ Siena, Dept Med Biotechnol, Div Cardiol, Siena, Italy
[18] AUSL Romagna, Osped Lugo, UO Cardiol, Lugo, Italy
[19] IRCCS Ist Auxol Italiano, San Luca Hosp, Dept Cardiol, Cardiomyopathy Unit, Milan, Italy
[20] AUSL Romagna, Osped Forli, UO Cardiol, Forli, Italy
[21] AUSL Romagna, Osped Cesena, UO Cardiol, Cesena, Italy
[22] Univ Milano Bicocca, Dept Med & Surg, Milan, Italy
[23] Osped Infermi, Cardiol Unit, Faenza, Italy
[24] Univ Genoa, Dept Internal Med, Genoa, Italy
来源
关键词
Cardiac amyloidosis; Disease stage; NAC score; Prognostic scoring; Wild-type transthyretin cardiac amyloidosis; ASSOCIATION; EFFICACY;
D O I
10.1002/ehf2.15091
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Disease staging and prognostic scoring in wild-type transthyretin-related cardiac amyloidosis (ATTRwt-CA) can be captured by two systems (NAC and Columbia scores). However, uncertainty remains as epidemiology of the disease is evolving rapidly. We evaluated features associated with staging systems across ATTRwt-CA patients from different diagnostic pathways, and their association with prognosis. Methods We performed an analysis on DIAMOND patients with available data to evaluate NAC and Columbia score. DIAMOND was a retrospective study from 17 Italian referral centres for CA, enrolling 1281 patients diagnosed between 2016 and 2021, and aimed at describing characteristics of pathways leading to ATTRwt-CA diagnosis. Of the original cohort, 811 patients were included in this analysis. Each patient had NAC and Columbia score calculated. Patients were grouped according to NAC and Columbia scoring classes. We described characteristics of patients according to staging classes and diagnostic pathways at diagnosis. Prevalence of early diagnoses, defined as NAC Ia, NYHA class I, no use of diuretics, no history of heart failure (HF) hospitalizations nor of atrial fibrillation prior to diagnosis, was investigated. Finally, prognostic variables were tested alone and grouped as NAC or Columbia scores in Cox univariate and multivariate regression analyses. Prognosis was investigated as all-cause mortality, in the whole population and dividing patients in HF versus other diagnostic pathways. Results Only 1% of the study population had an early ATTRwt-CA diagnosis. Distribution of prognostic variables and of NAC and Columbia classes was heterogeneous across diagnostic pathways. The prevalence of NAC III and Columbia III was higher in the HF diagnostic pathway, but all NAC and Columbia classes were present in all pathways. Both NAC and Columbia scores were associated with all-cause mortality at univariate Cox regression analysis in the whole population, in patients from the HF diagnostic pathway and in those from other pathways. At multivariate analysis, Columbia score remained significantly associated with the outcome, together with age at diagnosis, left ventricular ejection fraction and maximal wall thickness. Conclusions In this contemporary nationwide cohort, an ATTRwt-CA early diagnosis was very rare. Disease staging with NAC and Columbia scoring systems determined classes of patients with heterogeneous features. Both scores were significantly associated with mortality, but other variables also had prognostic significance.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy
    Porcari, A.
    Razvi, Y.
    Masi, A.
    Patel, R.
    Ioannou, A.
    Rauf, M. U.
    Venneri, L.
    Martinez-Naharro, A.
    Merlo, M.
    Sinagra, G.
    Lachmann, H.
    Wechalekar, A.
    Hawkins, P. N.
    Fontana, M.
    Gillmore, J. D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 356 - 356
  • [42] Val122Ile familial transthyretin (TTR) amyloid cardiomyopathy in African-American patients has a worse prognosis than wild-type TTR amyloid cardiomyopathy
    Falk, R. H.
    Geller, H. I.
    Mirto, T.
    Dupee, D.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 761 - 761
  • [43] Acute aortic dissection associated with wild-type transthyretin amyloid
    Mori, Shinichiro
    Hatae, Ryusuke
    Iwaki, Toru
    [J]. PATHOLOGY INTERNATIONAL, 2021, 71 (08) : 556 - 558
  • [44] Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid
    Yazaki, M
    Liepnieks, JJ
    Kincaid, JC
    Benson, MD
    [J]. MUSCLE & NERVE, 2003, 28 (04) : 438 - 442
  • [45] Prognostic Role of Cardiopulmonary Exercise Testing in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Treated With Tafamidis
    Dalia, Tarun
    Acharya, Prakash
    Chan, Wan-chi
    Sauer, Andrew J.
    Weidling, Robert
    Fritzlen, John
    Goyal, Amandeep
    Miller, Dana
    Knipper, Elaine
    Porter, Charles B.
    Shah, Zubair
    [J]. JOURNAL OF CARDIAC FAILURE, 2021, 27 (11) : 1285 - 1289
  • [46] A Simplified Machine Learning Algorithm for Identification of Patients At-risk for Wild-type Transthyretin Amyloid Cardiomyopathy
    Heitner, Stephen B.
    Masri, Ahmad
    Elman, Miriam R.
    Emir, Birol
    Nolen, Kim D.
    Schumacher, Jennifer
    Calambur, Veena
    Huda, Ahsan
    Bruno, Marianna
    Castano, Adam
    [J]. CIRCULATION, 2020, 142
  • [47] Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark
    Pilgaard, Trine
    Pedersen, Mikkel Hasse
    Poulsen, Steen Hvitfeldt
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (10) : 1084 - 1091
  • [48] Assessment of Physical Performance in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Evaluated by Cardiopulmonary Exercise Testing
    Willixhofer, R.
    Rettl, R.
    Kronberger, C.
    Duca, F.
    Binder, C.
    Kammerlander, A.
    Kastner, J.
    Bergler-Klein, J.
    Badr-Eslam, R.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S479 - S479
  • [49] Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin
    Hanson, Jacquelyn L. S.
    Arvanitis, Marios
    Koch, Clarissa M.
    Berk, John L.
    Ruberg, Frederick L.
    Prokaeva, Tatiana
    Connors, Lawreen H.
    [J]. CIRCULATION-HEART FAILURE, 2018, 11 (02)
  • [50] Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities
    Rapezzi, Claudio
    Serenelli, Matteo
    Aimo, Alberto
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (27) : 2633 - 2635